196 related articles for article (PubMed ID: 26313618)
1. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
3. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
[TBL] [Abstract][Full Text] [Related]
4. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
5. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
8. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
[TBL] [Abstract][Full Text] [Related]
9. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
10. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
11. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects.
Palmowski M; Huppert J; Ladewig G; Hauff P; Reinhardt M; Mueller MM; Woenne EC; Jenne JW; Maurer M; Kauffmann GW; Semmler W; Kiessling F
Mol Cancer Ther; 2008 Jan; 7(1):101-9. PubMed ID: 18202013
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.
Pysz MA; Machtaler SB; Seeley ES; Lee JJ; Brentnall TA; Rosenberg J; Tranquart F; Willmann JK
Radiology; 2015 Mar; 274(3):790-9. PubMed ID: 25322341
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
15. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
[TBL] [Abstract][Full Text] [Related]
16. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer.
Turco S; El Kaffas A; Zhou J; Lutz AM; Wijkstra H; Willmann JK; Mischi M
Mol Imaging Biol; 2019 Aug; 21(4):633-643. PubMed ID: 30225758
[TBL] [Abstract][Full Text] [Related]
18. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft.
Sugimoto K; Moriyasu F; Negishi Y; Hamano N; Oshiro H; Rognin NG; Yoshida T; Kamiyama N; Aramaki Y; Imai Y
J Ultrasound Med; 2012 Dec; 31(12):1909-16. PubMed ID: 23197543
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.
Zafarnia S; Bzyl-Ibach J; Spivak I; Li Y; Koletnik S; Doleschel D; Rix A; Pochon S; Tardy I; Koyadan S; van Zandvoort M; Palmowski M; Kiessling F; Lederle W
Neoplasia; 2017 Nov; 19(11):896-907. PubMed ID: 28938160
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
